ABSI News & Events

Skepticism crept into the "pathway to Iranian conflict offramp" narrative that boosted risky assets on Monday, and stocks fell on Tuesday, with Communication Services and Tech - particularly software names - suffering some of the bigger losses.  Tuesday evening, however, Israeli media reported that US negotiators are seeking a one-month ceasefire with Tehran as the two sides hammer out a status quo amenable to both administrations - the White House is hoping to secure promises of commitment from Tehran not to develop a nuclear arsenal or to support rogue militias in exchange for helping the country develop a nuclear program for energy use.  Separately, the WSJ also reported that mediators from Turkey, Egypt and Pakistan are working to secure a dialogue between Tehran and Washington.  S&P 500 futures reopened up 0.7% on the latest developments while WTI Crude Oil retreated further below $89 per barrel.Among notable movers afterhours, Braze spiked 20% after the company's better than expected Q4 revenue with above-consensus top-line guidance.  KB Home, however, was lower after a Q1 earnings miss, with homes delivered falling 14% from last year and average selling price compressing to $452,100, from $500,700, sending housing gross margins down to 15.5% from 20.3%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Brazeup 20.1%Paysignup 2.7%ALSO HIGHER -Robinhood Marketsup 1.9% after announcing $1.5B buybackDOWN AFTER EARNINGS -Abscidown 14.1%Velo3Ddown 9.3%KB Homedown 4.2%Worthington Enterprisesdown 2.6%GameStopdown 0.2%ALSO LOWER -Forgent Power Solutionsdown 10.6% after equity offeringDigitalOcean Holdingsdown 8.4% after equity offering

Reports Q4 revenue $650,000, consensus $1.38M. "Over the past year, we advanced ABS-201 from preclinical to three dosed cohorts in our HEADLINE trial with favorable emerging safety data, extending our track record of moving from AI design to clinic in approximately two years at a fraction of industry cost," said Sean McClain, founder and CEO. "Dr. Ransi Somaratne has joined as our first Chief Medical Officer to lead clinical execution and strategy. We are focused on delivering interim proof-of-concept data in the second half of 2026 and initiating our endometriosis Phase 2 by year-end. In AGA and endometriosis, there is a significant unmet need, as no approved disease-modifying therapeutic options exist for these patients. This is the kind of whitespace where we believe our AI-native drug creation strategy can generate the most value."